Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

Table 1 Patient demographics and clinical characteristics

	NGX-4010 (n = 102)	Control (n = 53)
Demographics
Age (yr), mean ± SD	68.7 ± 12.00	71.2 ± 11.26
Male, n (%)	47 (46%)	25 (47%)
Race
White	89 (87%)	45 (85%)
Black or African American	6 (6%)	3 (6%)
Asian	1 (1%)	1 (2%)
American Indian or Alaska Native	0 (0%)	1 (2%)
Native Hawaiian or Other Pacific Islander	0 (0%)	0 (0%)
Other	6 (6%)	3 (6%)
Clinical characteristics
Duration of Pain (yr), mean ± SD	2.7 ± 2.92	3.4 ± 4.00
Baseline ^a "Average Pain for the Past 24 Hours", mean ± SD	5.4 ± 1.58	5.3 ± 1.53
On Concomitant Pain Medication^b, n (%)	78 (76%)	42 (79%)
Opioids	26 (25%)	13 (25%)
Anticonvulsants	26 (25%)	18 (34%)
Antidepressants	10 (10%)	6 (11%)
Other	52 (51%)	30 (57%)
Size of Painful Area at Screening (cm²), mean ± SD	337.9 ± 226.46	334.2 ± 221.92

Baseline pain level was defined as the mean of all available non-biased Screening NPRS scores in that category.
A patient was defined as being on concomitant pain medication if pain medication started prior to day of treatment, continued on the day of treatment, and was taken for at least 7 days.

ISSN: 1471-2377